Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TARA
STRONG SELLProtara Therapeutics, Inc. · Healthcare · United States · $226M · Avg Vol: $3M/d
12
StockRankGet insider-trade alerts
Q
35
V
33
M
22
P/E (TTM)
—
ROE
-37.3%
D/E
0.0x
Dividend %
—
Loading 1Y...
PRICE (1Y)+3.6%
SMA 50SMA 200
Close
$4.04
RSI (14)
36.1
52W High
$7.82
From 52W High
0.5%
SCORE BREAKDOWN
Quality
35
ROIC
-35.3%20.9
ROE
-37.3%23.1
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-27.0%13.1
Piotroski
239.0
Int. Cover
—N/A
D/E Ratio
0.02x80.6
Current Ratio
15.69x92.8
Value
33
P/E (TTM)
—N/A
EV/EBITDA
-1.3x25.0
P/FCF
—N/A
P/B
1.2x78.5
P/S
—N/A
Div Yield
—N/A
Momentum
22
52W High %
52%27.7
RS 6M
-43%19.6
SMA 50/200
0.80x19.2
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-21%14.0
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$226M
P/E (Forward)
-2.4x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TARA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TARA | Protara Therapeutics, Inc.(you) | $226M | 12 | STRONG SELL |
| RNAC | Cartesian Therapeutics, Inc. | $232M | 12 | STRONG SELL |
| NBP | NovaBridge Biosciences | $205M | 11 | STRONG SELL |
| GALT | Galectin Therapeutics Inc. | $229M | 9 | STRONG SELL |
| OTLK | Outlook Therapeutics, Inc. | $263M | 11 | STRONG SELL |
| TRDA | Entrada Therapeutics, Inc. | $227M | 8 | STRONG SELL |
| AVXL | Anavex Life Sciences Corp. | $222M | 9 | STRONG SELL |
| NAUT | Nautilus Biotechnology, Inc. | $215M | 15 | STRONG SELL |
| SRZN | Surrozen, Inc. | $229M | 15 | STRONG SELL |
| TTRX | Turn Therapeutics Inc. | $254M | 10 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.5%